Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 110 of 144 pages ‹ First < 108 109 110 111 112 > Last ›
HSL4927
Caulfield T.
Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues.
Health Law Rev 2005; 13:(2-3):114-6
HSL4928
Caulfield T.
Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.
Health Law Rev 2005; 13:(2-3):58-61
HSL4929
Lemmens T.
Federal regulation of REB review of clinical trials: a modest but easy step towards an accountable REB review structure in Canada.
Health Law Rev 2005; 13:(2-3):39-50
HSL4944
Regnstrom K, Burgess DJ.
Pharmacogenomics and its potential impact on drug and formulation development.
Crit Rev Ther Drug Carrier Syst 2005; 22:(5):465-92
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=4847&uid=16313234&db=PubMed&url=http://www.begellhouse.com/journals/3667c4ae6e8fd136,0f80ebac03395679,22c907bb0f290242.html
HSL4988
Mastai R.
[Clinical practice and pharmaceutical industry: an always difficult relationship].
Acta Gastroenterol Latinoam 2005; 35:(4):209-10
HSL4992
Lau Y.
Is banning direct to consumer advertising of prescription medicine justified paternalism?
J Bioeth Inq 2005; 2:(2):69-74
HSL4993
Jordens C, Anderson L.
Should we be concerned about direct-to-consumer advertising of prescription drugs?
J Bioeth Inq 2005; 2:(2):61-2
HSL5098
Fernandez R, Gao C, Genkin W, Ghandi T, Graham R, Hou J, Hsu E, Hwang J.
Changing perspectives on dental advertising.
J Am Coll Dent 2005 Fall; 72:(3):24-6
HSL5099
Adamjee A, Alfi D, Agarwal D, Braithwaite Y, Chan J, Chey M, Cho H, Choi C.
What does the fact of advertising convey to patients?
J Am Coll Dent 2005 Fall; 72:(3):22-3
HSL5212
Cohen JG.
Recent developments in health law. Merck and the Vioxx decision: playing by the changing rules of the chemical exposure game
J Law Med Ethics 2005 Wint 00; 33:(4):866-9
HSL5238
Holbrook A, Grootendorst P, Willison D, Goldsmith C, Sebaldt R, Keshavjee K, Gaebel K.
Can current electronic systems meet drug safety and effectiveness requirements?
AMIA Annu Symp Proc 2005; 335-9
HSL5372
Regnier K, Kopelow M, Lane D, Alden E.
Accreditation for learning and change: quality and improvement as the outcome.
J Contin Educ Health Prof 2005 Sum; 25:(3):174-82
http://www3.interscience.wiley.com/cgi-bin/abstract/112093715/ABSTRACT?CRETRY=1&SRETRY=0
HSL5421
Jureidini JN, Tonkin A.
Suicide and antidepressants in children (editorial)
Australian Prescriber 2005; 28:110-1
http://www.australianprescriber.com/magazine/28/5/110/1/
HSL5439
Campo K, De Staebel O, Gijsbrechts E, van Waterschoot W.
Physicians' decision process for drug prescription and the impact of pharmaceutical marketing mix instruments.
Health Mark Q 2005; 22:(4):73-107
HSL5440
Macias W, Stavchansky Lewis L.
How well do direct-to-consumer, DTC, prescription drug web sites meet FDA guidelines and public policy concerns?
Health Mark Q 2005; 22:(4):45-71
HSL5441
Parker RS, Pettijohn CE.
Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians.
Health Mark Q 2005; 22:(4):27-43
HSL19040
Woloshin S, Schwartz LM, Welch HG
Patients and medical statistics. Interest, confidence, and ability.
J Gen Intern Med 2005; 20:(11):996-1000
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490265/?tool=pubmed
HSL5579
Mansfield PR, Raven MK, Jureidini JN.
Depressed youth, suicidality and antidepressants
MJA 2005; 183:(5):275-276
http://www.mja.com.au/public/issues/183_05_050905/letters_050905_fm-1.html
HSL5740
Curry TJ, Jarosch J, Pacholok , S.
Are Direct to Consumer Advertisements of Prescription Drugs Educational?: Comparing 1992 to 2002.
Journal of Drug Education 2005; 35:(3):217-232
HSL5753
Miller D .
Commentary: Psychologically Naive Assumptions about the Perils of Conflicts of Interest
Moore , D A, Cain , Dm , Loewenstein G. Conflicts of interest: Challenges and solutions in business, law, medicine, and public policy. New York, NY: Cambridge University Press 2005
HSL5784
Seamon MJ, Clauson KA.
Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.
J Herb Pharmacother 2005; 5:(3):67-86
HSL5842
Lambert BL, Lin SJ, Tan H.
Designing safe drug names.
Drug Saf 2005; 28:(6):495-512
HSL7411
Gilad J, Moran L, Schlaeffer F, Borer A.
Antibiotic drug advertising in medical journals.
Scand J Infect Dis 2005; 37:(11-12):910-2
http://www.ncbi.nlm.nih.gov/pubmed/16308229
HSL8777
Singh AR, Singh SA.
The connection between academia and industry
Mens Sana Monographs 2005; 3:(1):5-35
http://www.msmonographs.org/article.asp?issn=0973-1229;year=2005;volume=3;issue=1;spage=5;epage=35;aulast=Singh
HSL8778
Singh AR, Singh SA.
Public welfare agenda or corporate research agenda?
Mens Sana Monographs 2005; 3:(1):41-80
http://www.msmonographs.org/article.asp?issn=0973-1229;year=2005;volume=3;issue=1;spage=41;epage=80;aulast=Singh
HSL8824
Kassirer JP.
On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health
New York: Oxford University Press, USA 2005
http://www.oup.com/us/catalog/general/subject/Economics/Health/?view=usa&ci=9780195300048
HSL8825
Abramson J.
Overdosed America: The Broken Promise of American Medicine
New York: Harper Collins 2005
http://www.harpercollins.com/books/9780060568535/Overdosed_America/index.aspx
HSL8826
Moynihan R, Cassels A.
Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients
New York: Nation Books 2005
http://web.archive.org/web/20070416141611/http://www.nationbooks.org/book.mhtml?t=sickness
HSL8994
Moore DA, Cain DM, Loewenstein G, Bazerman MH.
Conflicts of Interest: Challenges and Solutions in Business, Law, Medicine, and Public Policy
New York: Cambridge University Press 2005
http://www.cambridge.org/catalogue/catalogue.asp?isbn=9780511128370&ss=fro
HSL19377
Wells G, Shea B, O'Connell D, Peterson J, Welch V, et al
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis
OHRI 2005
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
HSL9987
Lexchin J.
Intellectual propety rights and the Canadian pharmaceutical marketplace: Where do we go from here?
International Journal of Health Services 2005; 35:(2):237 - 256
http://baywood.metapress.com/(iurdbb45zrns2y55w4i3yn45)/app/home/contribution.asp?referrer=parent&backto=issue,2,13;journal,9,146;linkingpublicationresults,1:300313,1
HSL9988
Mintzes B, Lexchin J.
Do higher drug costs lead to better health?
Can J Clin Pharmacol 2005 Win; 12:(1):e22-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16055941&query_hl=8&itool=pubmed_DocSum
HSL10299
Narhi U, Vanakoski J, Sihvo S.
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects.
Clin Drug Investig 2005; 25:(4):243-8
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17523774
HSL12608
Harp TN, McKenna M, Shute N.
Media, law, and the public's health.
J Law Med Ethics 2005 Win; 33:(4):
http://www.ncbi.nlm.nih.gov/pubmed/16689163?dopt=Abstract
HSL13288
Kotabe M, Peloso A, Gregory GD, Noble G, MacArthur W, Neal C, Riege A.
International Marketing: An Asia Pacific Focus
Milton, Qld: John Wiley and Sons Australia, Ltd. 2005
http://web.archive.org/web/20060824005525/http://www.johnwiley.com.au/highered/im/index.htm
HSL16340
Grosjean O
La santé Ã quel prix? Bruxelles: Couleur Livres 2005
http://www.educationsante.be/es/article.php?id=672
HSL16347
Peneff J
La France malade de ses médecins Paris: Les empêcheurs de penser en rond 2005
http://doctorants.mshparisnord.org/actualite/article.php3?id_article=26
HSL16350
Urfalino P
Le grand méchant loup pharmaceutique. Angoisse ou vigilance? Paris: Textuel 2005
http://www.amazon.fr/grand-méchant-loup-pharmaceutique-vigilance/dp/2845971621
HSL17364
Rothman KJ, Greenland S.
Causation and causal inference in epidemiology.
Am J Public Health 2005; 95:
http://ajph.aphapublications.org/cgi/content/full/95/S1/S144?view=long&pmid=16030331
HSL19041
Schwartz LM, Woloshin S, Birkmeyer JD
How do elderly patients decide where to go for major surgery? Telephone interview survey.
BMJ 2005 8; 20:(11):996-1000
http://www.bmj.com/content/331/7520/821.long
HSL19385
Chintagunta PK, Desiraju R
Strategic Pricing and Detailing Behavior in International Markets
Marketing Science 2005; 24:(1):67-80
http://mktsci.journal.informs.org/cgi/content/abstract/24/1/67
HSL20030
Costa C, Papacosta C
Doctors versus Drug Reps: The Corruption of Medical Science
New Doctor 2005; 82:24-25
http://search.informit.com.au/documentSummary;dn=927871162682224;res=IELFSC
HSL725
Associated Press.
Eli Lilly Said to Know of Prozac Risks
Associated Press 2004 Dec 31
HSL727
Reuters .
FDA Warns Barr Over Seasonale Commercial
Reuters 2004 Dec 31
HSL5471
Mansfield PR, Jureidini JN, Parry P.
The belief that fluoxetine is effective for depressed children persists but is unjustified
BMJ 2004 Dec 31; 330:
http://bmj.bmjjournals.com/cgi/eletters/330/7481/7
HSL718
Meier B .
Medicine's Data Gap: Doctors, Too, Ask: Is This Drug Right?
The New York Times 2004 Dec 30
HSL726
Goldstein , R .
Intimidation, Politics and Drug Industry Cripple U.S. Medicine
Inter Press Service 2004 Dec 30
HSL730
Reuters.
Celebrex Prescriptions Plunge After Risks Identified
The Wall Street Journal 2004 Dec 30
HSL717
The ASSOCIATED.
Family of woman killed by AIDS test drug sues doctors
USA TODAY 2004 Dec 29
HSL777
Maher S.
US drug makers pressure Canberra
The Australian 2004 Dec 29
HSL712
Editorial .
Prescription for Confusion
THE NEW YORK TIMES 2004 Dec 28
HSL713
O'Connor , A .
Vioxx. Celebrex. Now Aleve. What's a Patient to Think?
The New York Times 2004 Dec 28
HSL703
Editorial /, S .
Take drugs off the market
USA Today 2004 Dec 27
HSL704
Rost P.
Big Pharma's Dirty Little Secret
The LA Times 2004 Dec 26
HSL705
Krasner , J .
Stents sold despite high failure rates: BSX held off recall amid alarming data
The Boston Globe 2004 Dec 26
HSL707
Editoral .
FDA warnings
The Boston Globe 2004 Dec 26
HSL708
Hensley , S .
New risks put old drugs in spotlight
The Wall Street Journal 2004 Dec 26
HSL714
Goldstein , S .
Bill would shield some drug firms from punitive damages: A provision in medical malpractice legislation would protect manufacturers that meet FDA standards.
Philadelphia Inquirer 2004 Dec 26
HSL774
Hudson P.
What's in it for me?
The Hearld Sun 2004 Dec 26
HSL700
O'Gilfoil Healy, P .
Spitzer, in a Shift, Will Yield Inquiries to U.S. Regulators
The New York Times 2004 Dec 25
HSL701
Henderson D.
Calls are mounting for revamp of FDA
The Boston Globe 2004 Dec 25
HSL702
Siegel M.
Put the Brakes on the Wonder Drug Express
The Washington Post 2004 Dec 25
HSL1637
Raphael MF, Bouts AH, Sukhai RN.
[Sweets from the pharmaceutical industry reason to suspect intoxication with quetiapine] .
Ned Tijdschr Geneeskd 2004 Dec 25; 148:(52):2583-4
HSL706
Kerber , R .
22% of medical device follow-up studies left undone
The Boston Globe 2004 Dec 24
HSL163
Silverman E.
Choosing their words carefully
NJ Star-Ledger 2004 Dec 23
HSL696
Editorial .
The Sick NIH
The LA Times 2004 Dec 23
HSL709
Medicare to Test Ways to End Disparities Amid Evidence That Closing Treatment Gaps Saves More Lives Than R&D
Washington Health Policy Week in Review 2004 Dec 23
HSL716
Reuters .
Aleve Warnings May Be Exaggerated
The Wall Street Journal 2004 Dec 23
HSL162
Willman D.
The National Institutes of Health: Public Servant or Private Marketer?
The Los Angeles Times 2004 Dec 22
HSL697
Willman , D .
$508,050 From Pfizer, but No 'Outside Positions to Note'
The LA Times 2004 Dec 22
HSL698
William D.
Case study| Dr. Lance A. Liotta and Emanuel F. 'Chip' Petricoin III: Firm's Research Stalls as Cancer Experts Work for Rival
The LA Times 2004 Dec 22
HSL699
William D.
Case Study| Dr. Harvey G. Klein: Public Pays for Blood Expert's Advice, and So Do Firms
The LA Times 2004 Dec 22
HSL715
Heavey , S .
FDA Says AstraZeneca Crestor Ad Is Misleading
Reuters 2004 Dec 22
HSL146
Maher S.
Heart monitor on arthritis drug
The Australian 2004 Dec 21
HSL156
Harris G.
A 4th Painkiller Is Tied to Increased Heart Risk
The New York Times 2004 Dec 21
HSL160
Goozner M.
Op-Ed Contributor: Overdosed and Oversold
New York Times 2004 Dec 21
HSL161
Rowland C.
Drug makers revamping clinical-trial system: New test strategies focus on weeding out duds sooner
The Boston Globe 2004 Dec 21
HSL144
Getting a Toehold for Research Comparing Medical Treatments
Washington Health Policy Week in Review 2004 Dec 20
HSL148
Saunders M.
Arthritis drug wins backing
The Australian 2004 Dec 20
HSL150
Pfizer to stop advertising painkiller: report
ABC News Online 2004 Dec 20
HSL710
Grassley Plays Up Role as Government Watchdog, Focuses on FDA
Washington Health Policy Week in Review 2004 Dec 20
HSL773
Harvey M, Frenkel J.
PBS fix-it plan to save billions
The Hearld Sun 2004 Dec 20
HSL722
Meier B .
Medicine Fueled by Marketing Intensified Trouble for Pain Pills
The New York Times 2004 Dec 19
HSL1
Mansfield P.
Accepting what we can learn from advertising's mirror of desire.
BMJ 2004 Dec 18; 329:(7480):1487-8
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=15604193
HSL139
New Doubts About Celebrex
THE NEW YORK TIMES 2004 Dec 18
HSL159
Pugh T, Borenstein S.
American Consumers Suffering as More New Drugs Debut in US, Analysis Shows
Knight-Ridder 2004 Dec 18
HSL739
Berenson , A .
Pricey Drug Trials Turn Up Few New Blockbusters
The New York Times 2004 Dec 18
HSL1638
Offerhaus L.
[The pharmaceutical industry in scandal: Mercury or Aesculapius?]
Ned Tijdschr Geneeskd 2004 Dec 18; 148:(51):2554-6
HSL2037
Scott T, Stanford N, Thompson DR.
Killing me softly: myth in pharmaceutical advertising.
BMJ 2004 Dec 18; 329:(7480):1484-7
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15604192
HSL129
Pfizer's statement on Celebrex: Firm finds one of two studies showed patients on Celebrex had an increased risk of heart attacks.
CNN 2004 Dec 17
HSL130
Hensley .
Pfizer Says Study Shows Heart Risk From Celebrex: Shares Sink 11% on News
Wall Street Journal 2004 Dec 17
HSL142
Pfizer Statement on New Information Regarding Cardiovascular Safety of Celebrex: Dosing in Long-Term Cancer Studies Suspended Due to Increased Cardiovascular Risk in One Study; Preliminary Analysis of Second Long-Term Cancer Study Shows No Increased Cardi
Pfizer.com 2004 Dec 17
HSL1197
Mandatory Reporting of Adverse Drug Reactions: An important first step
Canadian Women's Health Network 2004 Dec 17
HSL1989
Young T.
Medication Errors Involving Reminyl* and Amaryl
Janssen-Ortho Inc. & Aventis Pharma Inc.. 2004 Dec 17
HSL71
Sarasohn J.
Tauzin to Head Drug Trade Group
The Washington Post 2004 Dec 16
HSL76
Kaufman M.
Many FDA Scientists Had Drug Concerns, 2002 Survey Shows
The Washington Post 2004 Dec 16
HSL80
Bias seen in U.S. drug study reporting
United Press International 2004 Dec 16
HSL141
Prescription Drugs: About One-Fifth of FDA Scientists Felt Pressured To Approve Medications, Despite Safety Concerns, Survey Shows
Kaiser Daily Health Policy Report 2004 Dec 16
HSL723
Lueck , S .
Tauzin Is Named Top Lobbyist For Pharmaceuticals Industry: Departing Congressman Is Former Head of Panel That Oversaw Drug Sector
THE WALL STREET JOURNAL 2004 Dec 16
HSL771
Generics See Evergreening as Red
Corrs In Brief 2004 Dec 16
Page 110 of 144 pages ‹ First < 108 109 110 111 112 > Last ›
